Patents Assigned to STRM.bio Incorporated
  • Compositions and methods related to megakaryocyte-derived extracellular vesicles for treating myeloproliferative neoplasms
    Patent number: 12644134
    Abstract: Disclosed herein are compositions and methods related to treating myeloproliferative diseases or disorders, such as MPN, using megakaryocyte-derived extracellular vesicles, including megakaryocyte-derived extracellular vesicles derived from human pluripotent stem cells.
    Type: Grant
    Filed: October 23, 2021
    Date of Patent: June 2, 2026
    Assignee: STRM.bio Incorporated
    Inventor: Jonathan Thon
  • Compositions and methods related to megakaryocyte-derived extracellular vesicles for Fanconi Anemia
    Patent number: 12521449
    Abstract: Disclosed herein are compositions and methods related to megakaryocyte-derived extracellular vesicles derived from human pluripotent stem cells, where the megakaryocyte-derived extracellular vesicles may be utilized for treating Fanconi anemia (FA).
    Type: Grant
    Filed: April 26, 2022
    Date of Patent: January 13, 2026
    Assignee: STRM.bio Incorporated
    Inventors: Jonathan Thon, David Raiser, Laura Goldberg
  • Compositions and methods related to megakaryocyte-derived extracellular vesicles
    Patent number: 12090234
    Abstract: Disclosed herein are compositions and methods related to megakaryocyte-derived extracellular vesicles derived from human pluripotent stem cells, where the megakaryocyte-derived extracellular vesicles may be utilized for drug delivery and treating various diseases.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: September 17, 2024
    Assignee: STRM.bio Incorporated
    Inventor: Jonathan Thon